Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 556 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: no Condition Clear all
Terminated Phase 2 Interventional

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

NCT02498535
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide 160 ppm
Drug
Lead sponsor
Novoteris, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 27, 2026, 11:45 PM EDT
Terminated Not applicable Interventional

Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery

NCT00140608
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Seprapack Sinus Dressing
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Charleston, North Carolina • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Not applicable Interventional Results available

Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study

NCT05838417
View directory record Official record
Conditions
Breast Cancer
Interventions
REDS survey
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
39 Years to 49 Years · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 11:45 PM EDT
Not listed No phase listed Observational

Analysis of Crosslinked and Conventional Polyethylene Explants

NCT01484002
View directory record Official record
Conditions
Osteoarthritis
Interventions
Total hip arthroplasty
Device
Lead sponsor
Anderson Orthopaedic Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

NCT01143090
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lycopene in Healthy Male Participants

NCT00450957
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Prostate Cancer
Interventions
lycopene, pharmacological study
Dietary Supplement · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 27, 2026, 11:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

NCT01575548
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
579
States / cities
Fairbanks, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAMe for Hot Flashes

NCT01140646
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Hot Flashes
Interventions
S-adenosyl-L-methionine disulfate p-toluene-sulfonate, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

NCT03347292
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib(Stivarga, BAY73-4506), Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 27, 2026, 11:45 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration

NCT00896636
View directory record Official record
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
Random fine need aspiration (rFNA), Mammogram
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 27, 2026, 11:45 PM EDT
Not listed No phase listed Observational

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

NCT04100811
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
miR Scientific LLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
2,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Stockbridge, Georgia • Farmingdale, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Diindolylmethane in Preventing Cancer in Healthy Volunteers

NCT00784394
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
diindolylmethane, placebo, pharmacological study, laboratory biomarker analysis, quality-of-life assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 27, 2026, 11:45 PM EDT
Withdrawn Not applicable Interventional

Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors

NCT03120390
View directory record Official record
Conditions
Cancer Survivor, Central Obesity, No Evidence of Disease
Interventions
Best Practice, Exercise Intervention, Laboratory Biomarker Analysis, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 27, 2026, 11:45 PM EDT
Recruiting No phase listed Observational

Image Detection of Impaired Microcirculatory Reperfusion

NCT07099599
View directory record Official record
Conditions
Ischemic Stroke, Acute, Large Vessel Occlusion
Interventions
CT Perfusion
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.

NCT00614354
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
99mTc-glucarate solution
Drug
Lead sponsor
Molecular Targeting Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Birmingham, Alabama • New Haven, Connecticut • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

NCT01602380
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
12
States / cities
Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Racial Disparities in Pneumococcal Vaccination in Managed Care

NCT00229762
View directory record Official record
Conditions
Pneumococcal Disease Prevention
Interventions
phone call from nurses - informational only
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2005 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

NCT01204255
View directory record Official record
Conditions
Healthy
Interventions
lorazepam, diphenhydramine hydrochloride, haloperidol, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 27, 2026, 11:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 27, 2026, 11:45 PM EDT
Completed No phase listed Observational

Post-Market Study of the 3DKnee™ System

NCT00819481
View directory record Official record
Conditions
Degenerative Joint Disease, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis
Interventions
3DKnee™ System
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Fresno, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 27, 2026, 11:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of a Smart Growth Community's Effect on Prevention of Obesity in Middle-, Moderately Low- and Low-Income Families

NCT00986011
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Obesity, Weight Changes
Interventions
questionnaire administration, study of socioeconomic and demographic variables, survey administration, study of high risk factors
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 27, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy

NCT00086736
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, eflornithine, oral eflornithine placebo, oral bicalutamide placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 27, 2026, 11:45 PM EDT